Institutional members access full text with Ovid®

FDG-PET/CT for diagnosis of primary ovarian cancer

Kitajima, Kazuhiroa; Suzuki, Kayoa; Senda, Michiob; Kita, Masatoc; Nakamoto, Yujie; Onishi, Yumikod; Maeda, Tetsuod; Yoshikawa, Takeshid; Ohno, Yoshiharud; Sugimura, Kazurod

Nuclear Medicine Communications: July 2011 - Volume 32 - Issue 7 - p 549–553
doi: 10.1097/MNM.0b013e328345b339
Original Article

Background and aim: To evaluate the diagnostic value of integrated 18F-fluorodeoxyglucose (FDG) positron emission tomography and computed tomography (PET/CT) to discriminate malignant from benign ovarian tumors.

Methods: One hundred and eight women suspected of having ovarian cancer underwent preoperative FDG-PET/CT scans. FDG uptake was quantified by calculating the maximum standardized uptake value (SUVmax) of each tumor. The receiver operating characteristic curve was drawn to determine the optimal cut-off values of SUVmax that would best discriminate between benign and malignant tumors. Histopathologic results served as the reference standard. We assessed the association between SUVmax and with International Federation of Gynecology and Obsterics stage in borderline and malignant tumors, using one-factor analysis of variance and an unpaired t test with Bonferoni correction.

Results: The SUVmax of benign (n=26), borderline (n=12) and malignant (n=73) lesions was 2.00±1.02, 2.72±1.04, and 7.55±4.29, respectively. Although there were significant differences between benign and malignant, and borderline and malignant lesions (P<0.0001), there was no significant difference between benign and borderline lesions. Using an SUVmax cutoff of 2.55, the sensitivity, specificity and accuracy of FDG-PET/CT scanning to detect malignant or borderline tumors were 82.4, 76.9, and 81.1%, respectively. The SUVmax of stage I (n=35), stage II (n=8), stage III (n=34) and stage IV (n=8) was 3.59±2.32, 5.18±1.34, 8.72±2.69, and 15.05±3.77, respectively, and significant differences were observed between SUVmax values and the various International Federation of Gynecology and Obsterics stage (P<0.0001).

Conclusion: FDG-PET/CT scanning has a high diagnostic value in differentiating between malignant and benign tumors, and a low diagnostic value in differentiating between borderline and benign tumors.

aDepartments of PET Diagnosis

bMolecular Imaging, Institute of Biomedical Research and Innovation

cDepartment of Obsterics and Gynecology, Kobe City Medical Center General Hospital

dDepartment of Radiology, Kobe University Graduate School of Medicine, Kobe

eDepartment of Diagnostic Radiology, Kyoto University Hospital, Kyoto, Japan

Correspondence to Kazuhiro Kitajima, MD, PhD, Department of PET Diagnosis, Institute of Biomedical Research and Innovation, 2-2 Minatojima-Minamimachi, Chuo-ku, Kobe, Hyogo 650-0047 Japan Tel: +81 78 306 4605; fax: +81 78 382 6129; e-mail: kazu10041976@yahoo.co.jp

Received December 30, 2010

Accepted February 12, 2011

© 2011 Lippincott Williams & Wilkins, Inc.